The HLA screening test will be done by an investigational device. Patients must have the HLA-A*02:01 subtype to continue to the Main screening of the study. The Main screening will include medical tests and exams, including a tumor biopsy that will be tested for specific biomarkers by an investigational device called IMA201_Detect. Patients must be positive for at least one of the study's biomarkers to continue onto the leukapheresis part of the study.